Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Seattle Genetics reports phase II data on brentuximab vedotin in lymphoma

Oct. 13, 2010

ArQule and Daiichi Sankyo agree with FDA on SPA for phase III ARQ-197 trial

Oct. 13, 2010

Researchers synthesize new oncolytic gold complexes

Oct. 13, 2010

State University of New York, Albany claims novel antiestrogens

Oct. 13, 2010

Onyx Pharma delays NDA submission for carfilzomib

Oct. 11, 2010

MD Anderson Cancer Center investigates antitumor potential of CG-100649

Oct. 11, 2010

French scientists present new inhibitors of CDK1, CDK5 activator 1 and/or GSK-3

Oct. 11, 2010

Debio-0719 suppresses metastasis in mouse models of breast cancer

Oct. 11, 2010

PTC-299/aromatase inhibitor combinations deemed feasible in breast cancer trial

Oct. 11, 2010

ChemGenex completes pre-NDA meeting with FDA for Omapro

Oct. 8, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...